OCREVUS is a CD20-directed cytolytic antibody indicated for the treatment of patients with relapsing or primary progressive forms of multiple sclerosis.
IPN is a facilitator under Patient Assistance Programs. Expertise in Specialty Pharmaceutical distribution having its PAN India presence in Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, lucknow, north East and Pune and other cities in India. with over 20 years of domain experience.
For procurement cost of Ocrevus (Ocrelizumab) brand in India, sold by indian drug manufacturer. Please call at M: +91 9811747774 (Mr. Tarun) / 9891296838 (Mr. Neeraj) or Email Us to know more details about the OCREVUS (ocrelizumab) injection medicine cost price in India.
The order for Ocrevus (Ocrelizumab) will be confirmed only after the receipt of valid prescription of doctor and import permit if applicable.
Ocrelizumab (trade name Ocrevus) is a humanized anti-CD20 monoclonal antibody. It targets CD20 marker on B lymphocytes and hence is an immunosuppressive drug. Ocrelizumab binds to an epitope that overlaps with the epitope to which rituximab binds. It was approved by the FDA in March 2017 as a treatment for multiple sclerosis, and the first FDA approved drug for the primary progressive form of MS;
OCREVUS (ocrelizumab) injection, for intravenous use. Initial U.S. Approval: 2017
Generic Name: Ocrelizumab
Injection: 300 mg/10 mL (30 mg/mL) in a single-dose vial.
IPN helps patients, doctors and hospitals as a facilitator to import prescription medicine brand Ocrevus (Ocrelizumab) on prescription and Import License in Patient's Name only.
For overseas patients, Ocrevus (Ocrelizumab) can be made available in Send your enquiry to find Ocrevus (Ocrelizumab) in China, Cambodia, Indonesia, Malaysia, the Philippines, Singapore, Thailand, Vietnam, Hong Kong. UAE Iraq, Iran, Saudi Arabia, Jordan, Mexico, Argentina, Brazil, Chile, Colombia, Peru, Venezuela. Europe – Romania, Switzerland, Georgia, Turkey, Italy, UK, Ukraine, Azerbaijan, Latvia, Poland, Slovakia. Russia CIS – Armenia, Kazakhstan, Moldova, Tajikistan, Turkmenistan, Uzbekistan, Mongolia, Algeria, Mauritius, Uganda, Zimbabwe. Australia and New Zealand.